Files\\Communication from the Commission - § 3 references coded [ 0.50% Coverage]

Reference 1 - 0.18% Coverage

Key to this will be open and FAIR11 data sharing arrangements, which can lead to breakthrough discoveries and accelerate the development of health solutions.

Reference 2 - 0.17% Coverage

v Further develop the European COVID-19 Data Platform to encourage breakthrough discoveries and accelerate the development of health solutions.

Reference 3 - 0.16% Coverage

• The activation of emergency research and innovation plans and the use of Union wide clinical trial networks and data sharing platforms;

Files\\Communication from the Commission Annex - § 1 reference coded [ 0.20% Coverage]

Reference 1 - 0.20% Coverage

• IT platforms for MCMs

Files\\Proposal for a Council Regulation - § 4 references coded [ 0.60% Coverage]

Reference 1 - 0.08% Coverage

This should complement the smooth transition of data and information during public health emergencies at Union level, including via integrated IT systems.

Reference 2 - 0.31% Coverage

The Commission shall support access to relevant data from clinical trials, but also to real-world data. If possible, the Commission shall build upon existing preparedness research initiatives such as Union-wide networks for clinical trials and observational studies, or strategic cohorts, supported by digital platforms and infrastructures, such as high performance computing, enabling the open sharing of findable, accessible, interoperable and reusable (FAIR) data, as well as the activities of the national competent bodies supporting availability and access to data, including health data.

Reference 3 - 0.10% Coverage

Improve intelligence gathering, analysis and sharing on serious cross-border health threats, identify and address raw material dependencies as well as market and regulatory challenges/failures

Reference 4 - 0.10% Coverage

Improve intelligence gathering, analysis and sharing on serious cross-border health threats, identify and address raw material dependencies as well as market and regulatory challenges/failures